Selonterra

Executive Summary

Selonterra is a preclinical-stage biotechnology company headquartered in San Diego, California, founded in 2020. The company is dedicated to discovering and developing small molecule therapies for neurodegenerative disorders, employing a precision-medicine approach that leverages human genetics and gene regulatory networks. By targeting genetically linked mechanisms, Selonterra aims to create disease-modifying treatments rather than symptomatic relief. The company's platform integrates human genomic data to identify novel drug targets and patient populations most likely to benefit, potentially improving clinical trial success rates. As a private, early-stage entity, Selonterra has not disclosed its total funding or valuation but operates in a highly competitive landscape with significant unmet medical need in areas such as Alzheimer's, Parkinson's, and other neurodegenerative diseases. Further details on specific pipeline programs are not currently available, but the company's strategy is aligned with industry trends toward genetically informed drug development.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Announcement70% success
• Q4 2026Lead Program IND-Enabling Studies Initiation50% success
• Q1 2027Presentation of Preclinical Data at Major Conference80% success